Amivantamab Biosimilar – Anti-EGFR, ME, RCCP2 mAb – Research Grade

Reference:
Size

,

Brand

Product type

Clonality

Expression system

Description of Amivantamab Biosimilar - Anti-EGFR/ME/RCCP2 mAb - Research Grade

Description of Amivantamab Biosimilar - Anti-EGFR/ME/RCCP2 mAb - Research Grade

About Amivantamab biosimilar

Amivantamab is a bispecific monoclonal antibody with an enhanced FC-part. This antibody is part of the human immunoglobulin G1-kappa type. It is targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET, a receptor tyrosine kinase). Both of these factors have key roles in proto-oncogen pathways and invasive growth program.

A treatment by biosimilar recently approved

As Amivantamab biosimilar is targeting proto-oncogen signaling pathway, it is known to have an antineoplasic activity. Janssen Biotech has recently obtained the first approval for RYBREVANT (amivantamab-vmjw –an injection for intravenous infusion) by FDA to treat non-small cell lung cancer (NSCLC) in some conditions. There are also preregistrations in the European Union, Switzerland, Japan, China, Canada and Australia. To be used as a treatment, patients should be adults “with locally advanced or metastatic NSCLC harbouring EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy”, according to the FDA.

non-small cell lung cancer: some points

NSCLC is the most common kind of primary type of lung cancer(85% of lung cancers). This cancer is mostly treated using different types of therapy such as immunotherapy and targeted therapy. NSCLCs are carcinomas: this means that the cells developing invasive growth are located on the surface of all the airway parts (bronchi, bronchioles, and alveoli). Symptoms are especially including a chronic cough, chest pain and exhaustion.

A research grade biosimilar

Amivantamab biosimilar is the result of about ten years of research on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offers this product for research use only.

Product nameAmivantamab Biosimilar - Anti-EGFR, ME, RCCP2 mAb - Research Grade
SourceCAS 2171511-58-1
SpeciesHomo sapiens
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsJNJ-61186372,JNJ-6372
ReferencePX-TA1576
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
SourceCAS 2171511-58-1
Product nameAmivantamab Biosimilar - Anti-EGFR, ME, RCCP2 mAb - Research Grade
SourceCAS 2171511-58-1
SpeciesHomo sapiens
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsJNJ-61186372,JNJ-6372
ReferencePX-TA1576
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
SourceCAS 2171511-58-1

Reviews

There are no reviews yet.

Be the first to review “Amivantamab Biosimilar – Anti-EGFR, ME, RCCP2 mAb – Research Grade”

Your email address will not be published.


Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: